Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective.
Chia-Yu ChuTsung-Chieh YaoI-Hsin ShihChin-Yi YangChan Lee ChinSabeera Begum Binti Kader IbrahimSuganthi ThevarajahLeong Kin FonMarco Hok-Kung HoChow Chung MoChow Pok YuSteven King-Fan LooThomas A LugerPublished in: Dermatology and therapy (2023)
Atopic dermatitis (AD) is a common chronic, multisystem inflammatory skin disease in pediatric patients. There has been an increase in the incidence of AD in the pediatric population of the Asia-Pacific region. Studies have shown that genetic, epigenetic, environmental and cultural factors may lead to differences in the clinical manifestation and prevalence of AD between races. Early treatment of AD is necessary to prevent the atopic march leading to comorbidities such as asthma and allergic rhinitis. Topical corticosteroids (TCS) are used as first-line therapy for the treatment of AD, but their long-term usage poses a risk to the patient's health. Pimecrolimus (1%) is a topical calcineurin inhibitor (TCI) that is indicated for the treatment of mild to moderate AD. Pimecrolimus has no apparent increase in adverse events compared to TCS, and it causes less of a burning sensation than tacrolimus. The safety and efficacy of pimecrolimus has been established through various clinical trials; yet, in many Asian countries, the use of pimecrolimus in infants is still restricted due to safety concerns. Based on the available evidence, the expert panel recommends pimecrolimus in infants between 3 months and 2 years of age in the Asian population.
Keyphrases
- atopic dermatitis
- clinical trial
- healthcare
- allergic rhinitis
- randomized controlled trial
- magnetic resonance imaging
- gene expression
- chronic obstructive pulmonary disease
- computed tomography
- risk assessment
- wound healing
- climate change
- combination therapy
- health information
- clinical practice
- case control
- study protocol
- social media
- smoking cessation